$5.51
−1.78%Oct 8, 2026, 07:10 UTC
French pharmaceutical stocks Genfit, Nanobiotix and Valneva SE fell between 4.8% and 6.2%.
Source:Oct 7, 2026, 20:00 UTC
The United Kingdom’s Medicines and Healthcare products Regulatory Agency revoked Valneva’s marketing authorization for IXCHIQ following a benefit-risk assessment by the Commission on Human Medicines.
Source:Aug 14, 2026, 05:00 UTC
The European Medicines Agency validated the Marketing Authorization Application for Pfizer and Valneva's Lyme disease vaccine candidate PF-07307405 and will begin its assessment.
Aug 13, 2026, 05:00 UTC
Valneva SE implemented a restructuring program, with positive effects on income statement and cash flow expected in the second half of 2026.
Source:Aug 13, 2026, 05:00 UTC
Valneva SE reported its condensed consolidated financial results for the first half of 2026, provided corporate updates, and reaffirmed its financial guidance for 2026.